Report 12-week primary endpoint results from Phase 2 MoonStone trial in relapsing multiple sclerosis
Delivered after the deadline (27 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Feb 2025
- Due
- 30 Sep 2025
- Delivered
- 27 Oct 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Report the 12-week primary endpoint results in the third quarter of 2025 from the Phase 2 MoonStone trial in patients with RMS.”
What we found
Evidence strength A What the grades mean
Zenas BioPharma reported positive 12-week MoonStone primary endpoint results on October 27, 2025, about four weeks after the stated Q3 2025 (Sept. 30) deadline.
-
A Zenas BioPharma, Inc. - Form 8-K - FY2025 SEC 8-K referencing the already-reported MoonStone 12-week results as a Q3 update.
-
B Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis Press release announcing MoonStone 12-week primary endpoint results met, dated Oct 27, 2025.
-
D Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial Company investor relations page confirming same Oct 27, 2025 announcement.
-
D Zenas BioPharma Reports Q1 2025 Financial Results Q1 2025 update indicating MoonStone results anticipated early Q4 2025, later than original Q3 guidance.
Checked 13 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Zenas BioPharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ZBIO-000231 · Corrections policy